EDIT News and Press, Editas Medicine Inc. From 08/06/25

Sera Prognostics Inc. (SERA) is expected to report $-0.21 for Q2 2025 D/B/A Compass Diversified Holdings Shares of Beneficial Interest (CODI) is expected to report $0.51 for Q2 2025 Context Therapeutics Inc. (CNTX) is expected to report $-0.06 for Q2 2025 Genco Shipping & Trading ...

Editas Medicine Inc. (EDIT) is expected to report $-0.41 for Q2 2025

2025-07-30 16:57:48 ET Investment Overview Editas ( EDIT ) is a company I have not covered for Seeking Alpha in some time - since December 2022 in fact - largely because its share price has been in near constant decline, ever since hitting highs of >$90 per share in early...

2025-06-28 05:04:00 ET Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. Chasing short-term gains isn't the smartest way to invest, but hardly a month goes by without at least one stock fr...

2025-06-27 08:15:00 ET Over the past year, Editas Medicine (NASDAQ: EDIT) and Sarepta Therapeutics (NASDAQ: SRPT) , two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plumme...

2025-06-20 08:39:22 ET More on Editas Medicine Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) Editas Medicine: Do The Risks Outweigh The Rewards? RFK Jr. looks to fast track rare disease drug approvals (updated) Editas Me...

2025-06-17 10:29:37 ET More on Eli Lilly, Verve Therapeutics Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade) Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript Eli Lilly: If You Don't Buy On Weight Loss Pr...

2025-06-17 10:07:00 ET The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (NASDAQ: EDIT) is a promising clinical-stage company that has captured Wa...

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease a...

2025-05-28 09:50:11 ET More on related stocks: MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition Ginkgo Bioworks: Cost-Cutting Efforts Aren't Enough Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) Ocugen wins ...